For a long time, factory managers and procurement teams treated recycled resin like a bad compromise. The mindset was simple: ...
The FDA has approved Lipfendra, a once-daily oral PCSK9 inhibitor for adults with high LDL cholesterol. The pill offers an alternative to injections for patients who need further LDL reduction beyond ...
FDA has approved Lipfendra, developed by American pharmaceutical company Merck, for adults with high LDL cholesterol. It ...
Max Scherzer's 2026 season has been a rollercoaster, and now the Toronto Blue Jays veteran has dealt with a setback.
The FDA has approved a first-of-its-kind pill that can lower "bad" LDL cholesterol with a daily pill instead of a shot.
High cholesterol is one of the major risk factors for heart disease and stroke. While statins have been the most common ...
The clinical trials reviewed by the FDA found that adding Lipfendra to statin therapy reduced LDL cholesterol by approximately 56% to 60%.
Pittsburgh doctors on Thursday hailed government approval of a highly effective anti-cholesterol pill that had previously ...
The U.S. Food and Drug Administration has approved Merck's Lipfendra (enlicitide), making it the first oral PCSK9 inhibitor ...
For years, people with very high cholesterol who needed more than statins often had one major hurdle to overcome: injections.
Merck & Co. won US regulatory approval of a pill that rivals powerful injections for cutting dangerous cholesterol levels, ...
Merck’s pill, called Lipfendra, is a PCSK9 inhibitor, which works in a different way from a statin to lower cholesterol.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results